15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Ocular Therapeutix Inc, 10 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $18.00 to $31.00, a moderate spread. The average target of $25.40 sits 194% above the current $8.63. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.39 next quarter toward $-1.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy00%
Buy10100%
Hold00%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Ocular Therapeutix Inc.
As of Jul, 10 of 10 firms rate OCUL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
OCUL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.39
Range $-0.43 – $-0.32 · 4 analysts · +2% YoY
Next period, 4 analysts expect Ocular Therapeutix Inc to earn $-0.39 a share (range $-0.43 – $-0.32), versus $-0.38 a year earlier. Full-year consensus is $-1.55, growing to $-1.54 the year after.
REVENUE · NEXT QUARTER
$14.0M
Range $11.5M – $16.0M · 4 analysts · -4% YoY
Revenue is expected to reach $14.0M (range $11.5M – $16.0M), -3.6% year-over-year. Full-year consensus is $51.9M, rising to $120.3M next year.
Top analysts covering Ocular Therapeutix Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OCUL.
#1
Daniil Gataulin
Chardan Capital · Rank #36
Buy
$21.00+143.3% to target
Overall win rate
55%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #38
Buy
No targeton OCUL
Overall win rate
44%
+ Follow
#3
Serge Belanger
Needham · Rank #83
Buy
$18.00+108.6% to target
Overall win rate
48%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #177
Buy
$20.00+131.7% to target
Overall win rate
38%
+ Follow
#5
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$25.00+189.7% to target
Overall win rate
34%
+ Follow
OCUL stock forecast FAQ
What is OCUL's average 12-month price target?+
The 10 analysts with a live target average $25.40 for Ocular Therapeutix Inc over the next 12 months, ranging from a $31.00 high to a $18.00 low.
Is OCUL stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 10 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for OCUL?+
The Street-high target is $31.00 (Piper Sandler), and the Street-low is $18.00 (Needham). The average of all 10 active targets is $25.40.
How many Wall Street analysts cover OCUL?+
10 analysts have an active rating on Ocular Therapeutix Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering OCUL?+
Among analysts who currently cover OCUL, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $21.00 target.
What is Ocular Therapeutix Inc's projected EPS for next quarter?+
The consensus estimate is $-0.39 per share (range $-0.43 – $-0.32) across 4 analysts. Full-year EPS is projected at $-1.55, rising to $-1.54 the following year.
How much revenue is Ocular Therapeutix Inc expected to report next quarter?+
Consensus revenue is $14.0M (range $11.5M – $16.0M). Full-year revenue is projected at $51.9M, growing to $120.3M next year.
Have analysts been upgrading or downgrading OCUL lately?+
As of Jul, 10 of 10 firms rate OCUL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OCUL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Chardan Capital
